Last reviewed · How we verify

F-18 florbetapir

The Cleveland Clinic · FDA-approved active Small molecule Quality 5/100

F-18 florbetapir is a Small molecule drug developed by The Cleveland Clinic. It is currently FDA-approved. Also known as: Amyvid, Florbetapir-fluorine-18, 18F-AV-45.

At a glance

Generic nameF-18 florbetapir
Also known asAmyvid, Florbetapir-fluorine-18, 18F-AV-45
SponsorThe Cleveland Clinic
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about F-18 florbetapir

What is F-18 florbetapir?

F-18 florbetapir is a Small molecule drug developed by The Cleveland Clinic.

Who makes F-18 florbetapir?

F-18 florbetapir is developed and marketed by The Cleveland Clinic (see full The Cleveland Clinic pipeline at /company/the-cleveland-clinic).

Is F-18 florbetapir also known as anything else?

F-18 florbetapir is also known as Amyvid, Florbetapir-fluorine-18, 18F-AV-45.

What development phase is F-18 florbetapir in?

F-18 florbetapir is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing